Stockreport

GlycoMimetics reports data from Phase III AML treatment trial [Yahoo! Finance]

GlycoMimetics, Inc.  (GLYC) 
Last glycomimetics, inc. earnings: 5/1 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.glycomimetics.com/investor-relations
PDF The randomised, double-blind, placebo-controlled study has been assessing uproleselan plus one of two chemotherapy regimens: mitoxantrone, etoposide and cytarabine (MEC [Read more]